Document Detail

Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy.
MedLine Citation:
PMID:  20231521     Owner:  NLM     Status:  MEDLINE    
The urotensin system has been hypothesized to play an important role in the pathophysiology of diabetic nephropathy. In this multicenter, randomized, double-blind, placebo-controlled, 2-period crossover study, the effects of the urotensin receptor antagonist palosuran on urinary albumin excretion and blood pressure in hypertensive patients with type 2 diabetic nephropathy treated with a single blocker of the renin-angiotensin-aldosterone system were assessed. Patients with 24-hour albuminuria >0.5 and <3.0 g, systolic blood pressure >135 and <170 mm Hg, and/or diastolic blood pressure >85 and <110 mm Hg received both palosuran 125 mg BID and placebo for 4 weeks each. Fifty-four patients (20% women; mean age: 61.6 years, blood pressure: 155/84 mm Hg, and albuminuria: 1016 mg per 24 hours) were included in the per-protocol analysis. Palosuran did not affect albuminuria, blood pressure, glomerular filtration rate, or renal plasma flow significantly. These results question whether urotensin receptor antagonism represents a new treatment strategy in this high-risk patient population.
Liffert Vogt; Carlos Chiurchiu; Harbajan Chadha-Boreham; Parisa Danaietash; Jasper Dingemanse; Samy Hadjadj; Henry Krum; Gerjan Navis; Eric Neuhart; Aneliya I Parvanova; Piero Ruggenenti; Arend Jan Woittiez; Reuven Zimlichman; Giuseppe Remuzzi; Dick de Zeeuw;
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-03-15
Journal Detail:
Title:  Hypertension     Volume:  55     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-05-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1206-9     Citation Subset:  IM    
University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / prevention & control
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects,  physiology
Creatinine / urine
Cross-Over Studies
Diabetes Mellitus, Type 2 / complications*
Diabetic Nephropathies / complications*
Hypertension / complications*,  drug therapy*,  urine
Middle Aged
Quinolines / therapeutic use*
Receptors, G-Protein-Coupled / antagonists & inhibitors
Renin-Angiotensin System / drug effects
Urea / analogs & derivatives*,  therapeutic use
Urotensins / drug effects,  metabolism
Reg. No./Substance:
0/1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea; 0/Antihypertensive Agents; 0/Placebos; 0/Quinolines; 0/Receptors, G-Protein-Coupled; 0/UTS2R protein, human; 0/Urotensins; 57-13-6/Urea; 60-27-5/Creatinine; 9047-55-6/urotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Need for a new skin cancer management strategy.
Next Document:  Whole grape intake impacts cardiac peroxisome proliferator-activated receptor and nuclear factor kap...